|
Strain
|
e.g., Sprague-Dawley versus Fischer 344
|
|
Species
|
Rat, mouse, dog, pig, etc.
|
|
Age
|
Age in weeks, body weight
|
|
Gender
|
Male versus female versus mix of genders used
|
|
Model of PAH
|
MCT, CH, or SUHx
|
|
Severity of PAH
|
RVSP or mPAP in control group
|
|
Cell preservation
|
Fresh versus fresh from previously cryopreserved versus thawed cryopreserved product
|
|
Tissue source of regenerative cell product
|
Bone marrow versus peripheral blood versus cord blood
|
|
Timing of cell administration following induction of PAH
|
Early (<2 weeks) versus late (≥2 weeks) intervention
|
|
Follow-up duration
|
Primary outcome assessed at 1, 2, 3, and 4+ weeks after intervention
|
|
Route of cell administration
|
Intravenous versus intratracheal versus intraperitoneal versus intramuscular
|
|
Dose of cells
|
e.g., 1 × 106 cells
|
|
Type of control
|
PBS versus normal saline versus fibroblasts versus heat-killed cells
|
|
Cell modification
|
Yes versus No
|
|
Number of participating study centers
|
Single versus multi-center
|
